The Pharma Letter

Omeros rockets as FDA approves Yartemlea

Seattle, USA-based biotech Omeros Corp saw its shares leap 75.5% to $15.36 by close of trading Wednesday, as it revealed that ...
MedPage Today on MSN

First Drug for Deadly Transplant Complication Gets FDA's Blessing

The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy (TA-TMA) in adults and kids ages 2 years and up, ...
Pharmabiz

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...
MarketWatch

Omeros Gets FDA Approval of Yartemlea

Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...
Times Argus

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...
Nasdaq

Omeros Awaits FDA Decision On Lead Drug Candidate Narsoplimab Next Month

(RTTNews) - Omeros Corp. (OMER), a clinical-stage biopharmaceutical company focused on complement-mediated diseases, oncology, and addictive disorders, today announced its financial results for the ...
Fierce Pharma

Omeros scores its 1st FDA nod as stem cell transplant drug Yartemlea approved

Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the ...